FIRST WAVE BIOPHARMA (FWBI)
US33749P4081 - Common Stock
Taking everything into account, FWBI scores 1 out of 10 in our fundamental rating. FWBI was compared to 588 industry peers in the Biotechnology industry. FWBI has a bad profitability rating. Also its financial health evaluation is rather negative. FWBI does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year FWBI has reported negative net income.
FWBI had a negative operating cash flow in the past year.
FWBI had negative earnings in each of the past 5 years.
FWBI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
FWBI has a Return On Assets of -233.87%. This is amonst the worse of the industry: FWBI underperforms 91.10% of its industry peers.
The Return On Equity of FWBI (-446.80%) is worse than 78.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -233.87% | ||
| ROE | -446.8% | ||
| ROIC | N/A |
ROA(3y)-408.67%
ROA(5y)-343.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FWBI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, FWBI has more shares outstanding
FWBI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, FWBI has an improved debt to assets ratio.
2.2 Solvency
FWBI has an Altman-Z score of -43.72. This is a bad value and indicates that FWBI is not financially healthy and even has some risk of bankruptcy.
FWBI has a worse Altman-Z score (-43.72) than 93.15% of its industry peers.
A Debt/Equity ratio of 0.17 indicates that FWBI is not too dependend on debt financing.
FWBI has a worse Debt to Equity ratio (0.17) than 66.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -43.72 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
FWBI has a Current Ratio of 1.58. This is a normal value and indicates that FWBI is financially healthy and should not expect problems in meeting its short term obligations.
FWBI has a Current ratio of 1.58. This is amonst the worse of the industry: FWBI underperforms 81.68% of its industry peers.
FWBI has a Quick Ratio of 1.58. This is a normal value and indicates that FWBI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of FWBI (1.58) is worse than 80.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.58 |
3. Growth
3.1 Past
FWBI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.50%, which is quite impressive.
EPS 1Y (TTM)75.5%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q97.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
FWBI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.45% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.87%
EPS Next 2Y40.79%
EPS Next 3Y25.45%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FWBI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FWBI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
FWBI's earnings are expected to grow with 25.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.79%
EPS Next 3Y25.45%
5. Dividend
5.1 Amount
FWBI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FIRST WAVE BIOPHARMA
NASDAQ:FWBI (4/26/2024, 7:00:00 PM)
After market: 2.82 +0.08 (+2.92%)2.74
+0.01 (+0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.56M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -233.87% | ||
| ROE | -446.8% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.58 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)75.5%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y95.87%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y